Brady James Aloysius 4
4 · Xeris Biopharma Holdings, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Xeris Director Brady Aloysius Receives RSUs and Stock Options
What Happened Brady James Aloysius, a director of Xeris Biopharma Holdings, was granted two equity awards on June 4, 2026: 24,193 restricted stock units (RSUs) (recorded at $0) and 32,996 stock options with an exercise price of $6.15 (derivative grant) with an indicated aggregate grant value of $202,925 for the options. These were grants/awards (transaction code A) — not open-market purchases or sales.
Key Details
- Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely filing).
- RSUs: 24,193 shares, reported at $0 (contingent right to receive shares).
- Stock options: 32,996 option shares, exercise price $6.15, reported value $202,925 (derivative grant).
- Vesting: Both the RSUs and the options vest in full upon the earlier of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service (per filing footnotes).
- Shares owned after the transaction: Not specified in the Form 4 (not disclosed in the provided filing).
Context These entries are grant awards under Xeris’ 2018 Stock Option and Incentive Plan. The options were granted (not exercised) and the RSUs represent a contingent right to future shares — neither is an immediate sale or cash transaction. Because the filing was timely and lists clear vesting terms, retail investors can treat this as routine insider compensation rather than a direct market buy or sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-04+24,193→ 113,359 total - Award
Stock Option (Right to Buy)
[F2]2026-06-04$6.15/sh+32,996$202,925→ 32,996 totalExercise: $6.15Exp: 2036-06-04→ Common Stock (32,996 underlying)
Footnotes (2)
- [F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- [F2]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.